《艾昆纬（IQVIA）：2025 CAR-T细胞疗法发展之路：患者可及性障碍探析白皮书（英文版）（19页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬（IQVIA）：2025 CAR-T细胞疗法发展之路：患者可及性障碍探析白皮书（英文版）（19页）.pdf（19页珍藏版）》请在三个皮匠报告上搜索。

1、White PaperThe Path to CAR TCell Therapy Uncovering barriers to patient access SASHA LAUKS,MSc,Principal,IQVIA Strategy Consulting NICHOLAS GOULD,MSE,Associate Principal,IQVIA Strategy Consulting ELIZA BROSGOL,Consultant,IQVIA Strategy Consulting VALENTINA CEGLIA,PhD,Associate Consultant,IQVIA Strat

2、egy Consulting ADAM SOHN,MBA,Vice President,IQVIA Strategy ConsultingTable of contentsIntroduction 1Methodology 2Sample 2Overview of survey outputs 3Barriers experienced at a referring center 4Perceived patient ineligibility 4Patient hesitancy 5Coordination with ATCs 5ATC uncertainties 5Barriers exp

3、erienced at ATCs 6Poor patient health 6Perceived CAR T-cell therapy risks 7Perceived affordability challenges 7Logistics 7Priority solution areas 8Referring oncologists 8Treaters and administrators 9Patient advocacy groups 10Pharmaceutical manufacturers 10Conclusion 11Appendix 12References 14About t

4、he authors 16 |1CAR T-cell therapies generated intense anticipation ahead of their 2017 launch,offering a potentially transformative approach to combat cancers that experts had previously deemed incurable.1 Since initial authorization,CAR T therapies have expanded rapidly across multiple hematologic

5、 malignancies,now with six FDA-approved products addressing a broad range of relapsed or refractory B-cell lymphomas,leukemias,and multiple myeloma(Appendix,Table 1).2,3,4 These CAR T therapies have demonstrated superior efficacy compared to standard-of-care treatments and typically acceptable risk-

6、benefit profiles,prompting label updates that approved CAR T usage in earlier lines of therapy,and eliminated the FDAs Risk Evaluation and Mitigation Strategy(REMS)program.4,5In the United States,most patients begin their treatment journey at a practice likely located near their home.They are often